- Home
- PNI vs COYA Comparison
PNI vs COYA Comparison
Compare PNI & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- COYA
- Stock Information
- Founded
- PNI 2002
- COYA 2020
- Country
- PNI United States
- COYA United States
- Employees
- PNI N/A
- COYA N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- COYA Health Care
- Exchange
- PNI Nasdaq
- COYA Nasdaq
- Market Cap
- PNI 82.7M
- COYA 98.5M
- IPO Year
- PNI N/A
- COYA 2022
- Fundamental
- Price
- PNI $7.38
- COYA $6.41
- Analyst Decision
- PNI
- COYA Strong Buy
- Analyst Count
- PNI 0
- COYA 4
- Target Price
- PNI N/A
- COYA $16.25
- AVG Volume (30 Days)
- PNI 26.4K
- COYA 93.4K
- Earning Date
- PNI 01-01-0001
- COYA 03-18-2025
- Dividend Yield
- PNI 4.76%
- COYA N/A
- EPS Growth
- PNI N/A
- COYA N/A
- EPS
- PNI N/A
- COYA N/A
- Revenue
- PNI N/A
- COYA $9,554,315.00
- Revenue This Year
- PNI N/A
- COYA N/A
- Revenue Next Year
- PNI N/A
- COYA $56.22
- P/E Ratio
- PNI N/A
- COYA N/A
- Revenue Growth
- PNI N/A
- COYA N/A
- 52 Week Low
- PNI $6.03
- COYA $4.75
- 52 Week High
- PNI $7.89
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- PNI 62.02
- COYA 52.07
- Support Level
- PNI $7.25
- COYA $5.85
- Resistance Level
- PNI $7.32
- COYA $7.25
- Average True Range (ATR)
- PNI 0.08
- COYA 0.51
- MACD
- PNI 0.01
- COYA -0.04
- Stochastic Oscillator
- PNI 95.00
- COYA 32.94
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.